These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27291635)

  • 1. Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Montaudié H; Pradelli J; Passeron T; Lacour JP; Leroy S
    Br J Dermatol; 2017 Apr; 176(4):1060-1063. PubMed ID: 27291635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
    Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma.
    Fukuchi K; Hikawa M; Sano Y; Kasuya A; Aoshima M; Tatsuno K; Nakamura Y; Kosugi I; Tokura Y
    J Dermatol; 2019 Oct; 46(10):e359-e360. PubMed ID: 30985014
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary.
    Tulbah RI; Rowe SP; Solnes LB; Javadi MS
    Clin Nucl Med; 2019 Sep; 44(9):e519-e521. PubMed ID: 31348077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.
    Gauci ML; Baroudjian B; Laly P; Madelaine I; Da Meda L; Vercellino L; Bagot M; Lioté F; Pages C; Lebbé C
    Semin Arthritis Rheum; 2017 Oct; 47(2):281-287. PubMed ID: 28438383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab-induced organizing pneumonia in a melanoma patient.
    Sano T; Uhara H; Mikoshiba Y; Kobayashi A; Uchiyama R; Tateishi K; Yamamoto H; Okuyama R
    Jpn J Clin Oncol; 2016 Mar; 46(3):270-2. PubMed ID: 26759348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab: Immunotherapy in Malignant Melanoma.
    Bayless H; Schneider S
    Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
    Edmondson LA; Smith LV; Mallik A
    J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
    Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
    J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.
    Harada M; Naoi H; Yasuda K; Ito Y; Kagoo N; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Tsukui M; Koshimizu N
    BMC Pulm Med; 2021 Jan; 21(1):6. PubMed ID: 33407304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
    Ozaki Y; Shindoh J; Miura Y; Nakajima H; Oki R; Uchiyama M; Masuda J; Kinowaki K; Kondoh C; Tanabe Y; Tanaka T; Haruta S; Ueno M; Kitano S; Fujii T; Udagawa H; Takano T
    BMC Cancer; 2017 Nov; 17(1):778. PubMed ID: 29162045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case 286: Sarcoidlike Granulomatosis and Lymphadenopathy-Thoracic Manifestations of Nivolumab Drug Toxicity.
    Chiang J; Hebroni F; Bedayat A; Pourzand L
    Radiology; 2021 Feb; 298(2):471-475. PubMed ID: 33493088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral uveitis and macular edema induced by Nivolumab: a case report.
    Theillac C; Straub M; Breton AL; Thomas L; Dalle S
    BMC Ophthalmol; 2017 Dec; 17(1):227. PubMed ID: 29195497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.